Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00441064 · ClinicalTrials.gov registry record · Phase 4
Effect of High and Low Sodium Diets on Blood Pressure in Hypertensive Patients Treated With Aliskiren
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 132
- Enrollment target
NCT00441064 is a Phase 4 study that has completed, run by Novartis. The registered enrollment target is 132 participants.
The verdict
NCT00441064, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 132 participants
- Enrollment target
Study Summary
This study will compare the effects of high and low level sodium (salt) diets on blood pressure in patients with hypertension (high blood pressure) who are taking aliskiren 300 mg.
Interventions
- DRUG Aliskiren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2007-01 |
| Est. Completion | 2007-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00441064
The ClinicalTrials.gov registry entry for NCT00441064 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aliskiren is the first listed.
NCT00441064 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00441064 about?
NCT00441064 is a clinical study titled "Effect of High and Low Sodium Diets on Blood Pressure in Hypertensive Patients Treated With Aliskiren". This study will compare the effects of high and low level sodium (salt) diets on blood pressure in patients with hypertension (high blood pressure) who are taking aliskiren 300 mg.
What is the current status of trial NCT00441064?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 132 participants. The study started on 2007-01. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00441064?
The interventions under investigation include: Aliskiren (DRUG).
Who is sponsoring clinical trial NCT00441064?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.